Inhibition of 5α-reductase alters pregnane metabolism in the late pregnant mare

Michelle A A Wynn¹, Barry A Ball¹, Erin Legacki², Alan Conley², Shavahn Loux¹, John May³, Alejandro Esteller-Vico¹, Scott Stanley⁴, Kirsten Scoggin¹, Edward Squires¹ and Mats Troedsson¹

¹Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, Kentucky, USA, ²Department of Population Health and Reproduction, School of Veterinary Medicine, University of California, Davis, California, USA, ³College of Engineering, University of Kentucky, Lexington, Kentucky, USA and ⁴Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, California, USA

Correspondence should be addressed to B A Ball; Email: b.a.ball@uky.edu

Abstract

In the latter half of gestation in the mare, progesterone concentrations decline to near undetectable levels while other 5α-reduced pregnanes are elevated. Of these, 5α-dihydroprogesterone and allopregnanolone have been reported to have important roles in either pregnancy maintenance or fetal quiescence. During this time, the placenta is necessary for pregnane metabolism, with the enzyme 5α-reductase being required for the conversion of progesterone to 5α-dihydroprogesterone. The objectives of this study were to assess the effects of a 5α-reductase inhibitor, dutasteride on pregnane metabolism (pregnenolone, progesterone, 5α-dihydroprogesterone, 20α-hydroxy-5α-pregnan-3-one, 5α-pregnan-3β,20α-diol and allopregnanolone), to determine circulating dutasteride concentrations and to assess effects of dutasteride treatment on gestational parameters. Pregnant mares (n = 5) received dutasteride (0.01 mg/kg/day, IM) and control mares (n = 4) received vehicle alone from 300 to 320 days of gestation or until parturition. Concentrations of dutasteride, pregnenolone, progesterone, 5α-dihydroprogesterone, 20α-hydroxy-5α-pregnan-3-one, 5α-pregnan-3β,20α-diol, and allopregnanolone were evaluated via liquid chromatography–tandem mass spectrometry. Samples were analyzed as both days post treatment and as days prepartum. No significant treatment effects were detected in pregnenolone, 5α-dihydroprogesterone, 20α-hydroxy-5α-pregnan-3-one, 5α-pregnan-3β,20α-diol or allopregnanolone for either analysis; however, progesterone concentrations were increased (P < 0.05) sixfold in dutasteride-treated mares compared to control mares. Dutasteride concentrations increased in the treated mares, with a significant correlation (P < 0.05) between dutasteride concentrations and pregnenolone or progesterone concentrations. Gestational length and neonatal outcomes were not significantly altered in dutasteride-treated mares. Although 5α-reduced metabolites were unchanged, these data suggest an accumulation of precursor progesterone with inhibition of 5α-reductase, indicating the ability of dutasteride to alter progesterone metabolism.

Reproduction (2018) 155 251–258

Introduction

Progesterone (P4) is the primary hormone for pregnancy maintenance in most mammalian species (Challis et al. 2000, Conley 2016). Acting through the progesterone receptor (PR), P4 maintains myometrial quiescence and prevents premature parturition (Challis et al. 2000, Mendelson 2009). In contrast to other species, the mare has little detectable P4 in peripheral blood after mid-gestation (Short 1959, Holtan et al. 1991, Ousey et al. 2003, Scholtz et al. 2014). Although P4 levels rise dramatically during early pregnancy, analysis via mass spectrometry indicates that P4 concentrations begin to decline around 80 days of gestation and are undetectable by day 200 (Scholtz et al. 2014, Legacki et al. 2016b). Several pregnanes are present in high concentrations at this time, including 5α-dihydroprogesterone (DHP), 20α-hydroxy-5α-pregnan-3-one (20αP5), 5α-pregnan-

3β,20α-diol (βα-diol) and allopregnanolone (Chavatte et al. 1997, Ousey et al. 2003, 2005, Legacki et al. 2016a,b). Specifically, DHP is a direct metabolite of P4 and is known to bind the PR and maintain pregnancy in the absence of P4 (Challis et al. 2000, Chavatte-Palmer et al. 2000, Scholtz et al. 2014).

The key enzyme responsible for the conversion of P4 to DHP is 5α-reductase. Steroid hormones with a Δ⁴, 3-oxo structure, including pregnanes, glucocorticoids and androgens can be 5α-reduced by this enzyme (Russell & Wilson 1994), and equine 5α-reductase appears to act on Δ⁴, 3-oxo pregnenes (Raeside et al. 2015, Corbin et al. 2016). Of the two isoforms known to be present in the mare, 5α-reductase type 1 is the predominant isoform in the endometrium and chorioallantois of pregnant mares (Scholtz et al. 2014, Legacki et al. 2017a,b). Once 5α-reductase has metabolized P4 to DHP, DHP
can be further metabolized into a variety of 5α-reduced pregnanes including allopregnanolone. This hormone is a neuroactive steroid capable of binding GABA<sub>A</sub> receptors to enhance inhibitory neurotransmission (Bellegi & Lambert 2005) and is believed to have a sedative-like effect on the fetus (Madigan et al. 2012). In humans, horses and sheep, peripheral concentrations of allopregnanolone increase in both the maternal and fetal circulation, with levels peaking near term (Bicikova et al. 2002, Nguyen et al. 2003, Legacki et al. 2016a,b). Other DHP metabolites include 20α5P and βα-diol. The formation of these pregnanes is dependent upon enzyme metabolism within the uteroplacental tissue, and relative concentrations increase dramatically in mid-to-late gestation, similar to DHP (Legacki et al. 2016b). These pregnanes are of interest as they have been shown to activate the PR at prepartum peak concentrations in vitro (Legacki et al. 2016a), and they rely on P4 and DHP as steroidogenic precursors.

To demonstrate the importance of 5α-reductase on pregnancy metabolism and pregnancy, we evaluated the effects of dutasteride, a 5α-reductase inhibitor in pregnant mares, which has been previously shown to inhibit 5α-reductase in the horse in vitro (Corbin et al. 2016). Specifically, pregnane metabolism was monitored by measuring concentrations of specific pregnanes, and pregnancy outcome was evaluated in mares. It was hypothesized that administration of dutasteride to late pregnant mares would result in a decrease in DHP, 20α5P, βα-diol and allopregnanolone. With a decrease in these bioactive pregnanes, we further hypothesized a reduced gestational length in dutasteride-treated mares compared to control mares. The objectives for the current study were to assess changes in target pregnanes (P4, P5, DHP, 20α5P, βα-diol and allopregnanolone) and neonatal outcome in pregnant mares treated with dutasteride compared to controls. Concentrations of dutasteride in the maternal and neonatal circulation, neonatal weight, as well as neonatal viability were determined.

**Materials and methods**

**Animal husbandry**

Nine healthy light-breed broodmares with a mean age of 9.7 years (±1.2 year) were used in this study. Mares were maintained at the Maine Chance Farm, Department of Veterinary Science, University of Kentucky, Lexington, KY, and all experimental protocols were approved by the Institutional Animal Use and Care Committee at the University of Kentucky (Protocol #2012-1067). Gestational age was determined relative to day of ovulation (Day 0). Pregnant mares were maintained on pasture and supplemented with grain, water, hay, salt and trace minerals were available ad libitum. When parturition was suspected via determination of milk pH (Canisso et al. 2013), mares were moved to individual box stalls for the night to monitor parturition.

**Study design**

Pregnant mares were randomly assigned to treatment (n=5) or (n=4) control groups. Beginning on day 298 of gestation, jugular venous blood samples were taken daily in 10-mL heparinized tubes and 10-mL plain tubes (Becton, Dickinson and Company, Franklin Lakes, NJ, USA), and blood sampling continued through parturition. Blood samples were centrifuged at 1811 g for ten minutes, and plasma and serum were stored at −20°C until analysis. Beginning at day 300 of gestation, treated mares received intramuscular (IM) injections of dutasteride (Aurum Pharmaceuticals; Franklin Park, NJ, USA) at 0.01 mg/kg body weight, in an ethanol/myglyol (Thermo Fisher Scientific; Warner Graham Company, Cokessville, MD, USA) vehicle (60:40, ethanol:myglyol), and control mares received IM injections of vehicle alone. Dutasteride dosage was extrapolated from humans where the elimination half-life is known to be long (3–5 weeks) (Evans & Goa 2003). Dutasteride or vehicle control administration continued daily until day 320 of gestation or until parturition. Upon mammary development, milk samples were monitored for pH, to assess impending parturition. When milk pH neared 7.0, a FOAL ALERT sensor (Foal Alert. Inc., Acworth, GA, USA) was sutured to the vulva, per manufacturer’s instructions. Immediately after parturition, blood was collected from the neonate and mare via jugular venipuncture. After foaling, weights of the neonate and mare were recorded.

**Steroid analysis**

Plasma concentrations of P5, P4, DHP, 20α5P, βα-diol and allopregnanolone (Table 1) were determined via liquid chromatography-tandem mass spectrometry (LC/MS–MS). Samples were analyzed every other day beginning at day 298 of gestation and then daily for nine days prior to parturition. Pregnant concentrations were determined as previously reported with an accuracy >90%, precision <15% and average limit of quantification of 0.33 ng/mL (Legacki et al. 2016b).

**Determination of circulating dutasteride concentrations**

Dutasteride concentrations were analyzed at the University of Kentucky Environmental Research Training Laboratory, utilizing a modified protocol (Contractor et al. 2013). In short, dutasteride was measured from serum with a Varian 410 auto sampler, Varian ProStar 210 pumps and a Varian 1200L triple quadrupole mass spectrometer (Walnut Creek, CA, USA). This method utilized a Kinetex C18 column (100 x 2.1 mm x 2.6 µm) (Phenomenex, Torrance, CA, USA), with mobile phase A consisting of water with 0.1% formic acid and mobile phase B consisting of methanol with 0.1% formic acid. Ionization was achieved by electrospray ionization. Elution gradient (Table 2) and the reporting limit, quality controls (QC), ions, extraction efficiency, accuracy and precision (Table 3) were determined. The internal standard, dutasteride-13C6 (Clearsynth; Mississauga, ON, Canada), was dissolved in methanol at a working concentration of 100 ng/mL. Standards were made by dissolving dutasteride (Aurum Pharmaceuticals; Franklin Park, NJ, USA) in methanol at an initial concentration of 100,000 ng/mL. Charcoal-stripped
Inhibition of 5α-reductase in late pregnant mares

Results

Foaling outcome

All mares in the study delivered viable foals; however, one of the foals from a control mare had a severe omphalophlebitis and a patent urachus and was humanely killed at 5 days of age. Gestational lengths, neonatal weight and neonatal weight as a proportion of mare weight were not different between dutasteride-treated and control mares (Table 4). Three of the dutasteride-treated mares retained their placenta beyond three hours postpartum, but no control mares retained their placenta. Median placental weights were greater ($P < 0.05$) in dutasteride-treated ($n = 4$) than those in control ($n = 3$) mares.

Peripheral pregnane (P5 and P4) and 5α-reduced pregnane concentrations

For the period between 298 and 320 days of gestation, pregnane concentrations were evaluated in alternate day samples. For P4, there was an effect of time ($P < 0.0001$) and a time by treatment interaction ($P = 0.0003$; Fig. 1), and P4 was higher ($P < 0.05$) in dutasteride-treated mares at Days 314, 316, 318 and 320 of gestation with a six-fold difference in P4 concentrations at Day 320. An effect of time ($P < 0.01$) was detected for P5, 20α5P and $\beta\alpha$-diol, but there was no time, treatment or time-by-time-effect on concentrations of DHP or allopregnanolone between Days 298 and 320 (Fig. 1). For the nine days preceding parturition, there was a time effect ($P < 0.0001$) on P5, DHP, 20α5P and $\beta\alpha$-diol and allopregnanolone with each of these pregnanes decreasing in the three days preceding parturition.

Table 2  Elution gradient.

<table>
<thead>
<tr>
<th>Time</th>
<th>%A</th>
<th>%B</th>
<th>Flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:00</td>
<td>50</td>
<td>50</td>
<td>0.2</td>
</tr>
<tr>
<td>00:30</td>
<td>50</td>
<td>50</td>
<td>0.2</td>
</tr>
<tr>
<td>07:00</td>
<td>5</td>
<td>95</td>
<td>0.2</td>
</tr>
<tr>
<td>09:00</td>
<td>5</td>
<td>95</td>
<td>0.2</td>
</tr>
<tr>
<td>10:00</td>
<td>50</td>
<td>50</td>
<td>0.2</td>
</tr>
<tr>
<td>18:00</td>
<td>50</td>
<td>50</td>
<td>0.2</td>
</tr>
</tbody>
</table>

Mobile phase A consisted of water with 0.1% formic acid, and B consisted of methanol with 0.1% formic acid. Flow rate was 0.2 mL/min.
Table 3 LC–MS/MS details.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Rt</th>
<th>Precursor ion</th>
<th>Daughter ions</th>
<th>Reporting limit</th>
<th>QCH CV/%Acc</th>
<th>QCM CV/%Acc</th>
<th>QCL CV/%Acc</th>
<th>%EE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutasteride</td>
<td>7.8</td>
<td>529</td>
<td>461, 264, 187</td>
<td>0.1</td>
<td>4.8/97.8</td>
<td>5.9/97.6</td>
<td>4/109.7</td>
<td>83.6</td>
</tr>
<tr>
<td>Dutasteride 13C6</td>
<td>7.8</td>
<td>535</td>
<td>467, 270, 187</td>
<td>0.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>86.7</td>
</tr>
</tbody>
</table>

Compounds listed with retention time (Rt) in minutes, precursor ions, daughter ions, reporting limit, precision (%CV) and accuracy (%Acc) of quality controls (QCH, QCM and QCL) and extraction efficiency (%EE). Daughter ions are listed in order of abundance, with the ion of quantification bolded. Reporting limit is listed in ng/mL and was determined by the lowest standard visible with a linear curve. Precision and accuracy for QCH, QCM and QCL were determined by two runs containing triplicates of each QC. Percent accuracy was assessed by dividing the average QC values by the actual values and multiplying by 100. Extraction efficiency was calculated by dividing the area of the peak with extraction for dutasteride by the area of the peak without extraction for dutasteride and multiplied by 100.

(Fig. 2). For P4, there were effects of time (P<0.0001) and a time-by-treatment interaction (P=0.01) such that P4 was greater (P<0.05) in dutasteride-treated mares at Days −7, −6, −5, −4, −3 and −2 prior to parturition (Fig. 2). Neonatal pregnane concentrations were not different between foals from dutasteride-treated or control mares (Table 5).

**Dutasteride in circulation**

To assess circulating dutasteride concentrations, samples from treated mares were analyzed every four days, beginning from Day 298 and continuing through parturition (Fig. 3), along with a single sample from each of the treated foals to determine if dutasteride could cross the placenta. Two samples were selected at random from each control mare to include in the analysis. Overall, a time-dependent increase of dutasteride continued for the duration of the treatment. Two mares which foaled after administration of the final treatment exhibited a continual increase in dutasteride concentrations beyond Day 320. No dutasteride was detected in the control mares. In dutasteride-treated mares, there was a positive correlation between dutasteride concentrations and concentrations of P5 and P4; however, there was no significant correlation between dutasteride concentrations and either DHP or allopregnanolone (Fig. 4). Dutasteride concentrations were 22.7 ± 6.7 ng/mL for the single sample taken from the foals of treated mares at birth, but none detected in control foals. Mean concentrations of dutasteride in neonatal circulation were 53% of maternal dutasteride concentrations, and neonatal and maternal concentrations of dutasteride were highly correlated at parturition (r = 0.98; P<0.0035) in mares treated with dutasteride.

**Discussion**

Administration of the 5α-reductase inhibitor, dutasteride, to mares in late gestation did not significantly alter peripheral concentrations of DHP or its downstream metabolites (20α5P, βα-diol, or allopregnanolone). However, administration of dutasteride did increase peripheral concentrations of the precursor, P4, sixfold in treated mares over controls by the end of treatment. Previously, Ousey and coworkers reported that administration of the related steroidal, 5α-reductase inhibitor, finasteride, beginning at D300 of gestation also increased concentrations of P4 without decreasing concentrations of DHP (Ousey et al. 2001). Ousey and coworkers reported a reduced gestation length in mares treated with the 5α-reductase inhibitor, finasteride, and although gestational lengths in the current study were not significantly reduced, dutasteride-treated mares did have numerically lower median gestation lengths. Both studies were limited by small animal numbers, as well as by the variable length of normal gestation in mares.

In the mare, a normal prepartum rise in circulating pregnanes occurs approximately 30 days before parturition, followed by a rapid decline in the days or hours prior to foaling (Seamans et al. 1979, Hamon et al. 1991, Legacki et al. 2016a,b). In the current study, changes in measured 5α-reduced pregnanes in control and treated mares appeared similar to those previously reported (Legacki et al. 2016a,b) but dutasteride significantly increased P4, increasingly so as dutasteride concentrations rose. Dutasteride concentrations continued to increase beyond the end of treatment at D320 of gestation in treated mares that foaled later, and concentrations of the substrate, P4, also increased consistent with continued inhibition of 5α-reductase in these mares.

The potential mechanism for reduced gestational lengths with inhibition of 5α-reductase is unclear. There

Table 4 Gestational length and neonatal outcome.

<table>
<thead>
<tr>
<th>Group</th>
<th>Gestation length (days)</th>
<th>Neonatal weight (kg)</th>
<th>Neonatal/mare weight (%)</th>
<th>Placental weight (kg)</th>
<th>Neonatal gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutasteride</td>
<td>323 (318, 335)</td>
<td>51 (42, 55)</td>
<td>0.085 (0.073, 0.090)</td>
<td>4.7 (4.5, 5.0); n=4</td>
<td>4</td>
</tr>
<tr>
<td>Control</td>
<td>337 (321, 352)</td>
<td>40 (37, 62)</td>
<td>0.071 (0.062, 0.086)</td>
<td>3.1 (2.3, 3.8); n=3</td>
<td>2</td>
</tr>
</tbody>
</table>

Medians differ (*p <0.05). Data represent the median with the 25th and 75th quartile indicated in parenthesis.
is a marked downregulation of 5α-reductase activity and mRNA in the postpartum placenta of normal foaling mares compared to the placenta of mares at 10 months of gestation (Legacki et al. 2017b). This reduction in 5α-reductase activity in the placenta is associated with a dramatic decline in 5α-reduced pregnanes, including DHP, shortly before parturition (Legacki et al. 2016a). In the current study, reductions in circulating 5α-reduced pregnanes were noted in both dutasteride-treated and control mares in the three days preceding parturition, but 5α-reduced pregnanes were not different between groups in this period. Although normal parturition in the mare is associated with decreased 5α-reductase activity in the placenta and a reduction in peripheral 5α-reduced pregnanes, inhibition of 5α-reductase with either finasteride or dutasteride did not achieve reductions in 5α-reduced pregnanes or clear reductions in gestational length.

Although circulating concentrations of 5α-reduced pregnanes were unchanged, elevations in progesterone associated with 5α-reductase inhibition were noted in both the current study as well as the previous abstract from Ousey and coworkers. However, the potential role of elevations in P4 in the last month of gestation is unclear. Administration of the synthetic progestin, altrenogest, to mares in late gestation (>280 days) tended to shorten gestational length in mares (Neuhauser et al. 2008), and Alm and coworkers reported that administration of progesterone (500 mg daily) to pregnant mares beginning at 318 days of gestation significantly reduced gestational lengths (Alm et al. 1975). Unfortunately, no data on circulating concentrations of pregnanes are available in the Alm study, so it is not possible to know how circulating concentrations of progesterone and DHP were affected by their exogenous progesterone treatment. Effects of elevations in progesterone on reduced gestational length in mares, if any, remain poorly understood.

It is unclear whether altered placental expulsion and increased placental weights were associated with the recorded elevations in progesterone concentrations in dutasteride-treated mares. Treatment of mares with the synthetic progestin, altrenogest, during pregnancy did not alter placental retention time or weight (Shoemaker et al. 1989, Neuhauser et al. 2008). In cattle, Chew and coworkers (Chew et al. 1977) reported...
increased peripartal progesterone concentrations in cattle with retained fetal membranes; however, most authors have not found an association between elevations in peripartal progesterone and retained placenta in cattle (Agthe & Kolm 1975, Peter & Bosu 1987, Wischral et al. 2001, Takagi et al. 2002). The major interest in 5α-reductase inhibitors has focused primarily on their use to reduce conversion of testosterone to the more biopotent 5α-dihydrotestosterone in humans (Olsen et al. 2006, Aggarwal et al. 2010) with less interest in their ability to inhibit reduction of P4 to DHP. Dutasteride significantly reduced conversion of P4 to DHP in both mice (in vivo) and humans (in vitro) (Dong et al. 2001, Wiebe et al. 2006), as well as in the equine epididymis (Corbin et al. 2016) and equine embryo (Raeside et al. 2015). In human breast tissue, dutasteride resulted in not only a reduction of 5α-reductase activity, but also significantly increased expression of the enzymes 3α-hydroxysteroid oxidoreductase (3αHSOR) and 20α-hydroxysteroid oxidoreductase (20αHSOR) (Wiebe et al. 2006), which are necessary for metabolism of DHP to allopregnanolone and 20α5P. This suggests dutasteride would decrease the levels of DHP and other downstream metabolites in treated mares and also potentially increase 20α5P, βα-diol and allopregnanolone concentrations. However, at the dosage used in the current study, concentrations of these 5α-reduced pregnanes remained unchanged after administration of dutasteride. There was, however, a significant increase in P4 in dutasteride-treated mares that was consistent with a buildup of substrate due to at least partial enzyme inhibition.

In humans, dutasteride is reported to be 100 times as potent at inhibiting the type-1 isoform of 5α-reductase compared to finasteride (Olsen et al. 2006); therefore, dutasteride was expected to have a greater biopotency in this study when compared to the earlier report with finasteride in pregnant mares (Ousey et al. 2001). However, based upon in vitro observations using equine epididymis as the source of 5α-reductase, both dutasteride and finasteride inhibit the type-1 isoform of this enzyme with equal potency based on inhibition of the metabolism of P4 to DHP in vitro (Corbin et al. 2016). This is in contrast to potency differences reported in humans based upon inhibition of the reduction of testosterone to dihydrotestosterone by 5α-reductase (Olsen et al. 2006). After intramuscular administration of dutasteride, concentrations of the inhibitor rose slowly and continued to rise in mares after cessation of administration at D320 for approximately 10 days. No

Table 5 Concentrations of pregnanes and dutasteride in neonatal foals.

<table>
<thead>
<tr>
<th>Group</th>
<th>Pregnenolone</th>
<th>Progesterone</th>
<th>DHP</th>
<th>Allopregnanolone</th>
<th>Dutasteride</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dutasteride</td>
<td>725.5±140.2</td>
<td>3.3±0.6</td>
<td>21.8±2.4</td>
<td>3.8±1.4</td>
<td>22.7±6.7</td>
</tr>
<tr>
<td>Control</td>
<td>834±308.6</td>
<td>2.5±0.7</td>
<td>24.6±8.7</td>
<td>4±1.9</td>
<td>0</td>
</tr>
</tbody>
</table>

Concentrations of pregnanes and dutasteride (ng/mL) in neonatal foals born to dutasteride-treated and control mares. No significant differences were observed between groups. Data are mean ± s.e.m.

Figure 3 Dutasteride concentrations in treated mares. Graph shows the increase in dutasteride concentration during and post treatment for the five treated mares. The x-axis indicates days of gestation, and concentrations of dutasteride are shown along the y-axis in ng/mL. The vertical dotted line indicates the last day of treatment, with mares 1 and 2 foaling prior to the end of treatment.

Figure 4 Regression plots for pregnanes and dutasteride concentrations. Measured concentrations of dutasteride and selected pregnanes in mares treated with dutasteride from 298 to 320 days of gestation. For each graph, progesterone concentration is indicated along the y-axis in ng/mL and dutasteride concentration along the x-axis in ng/mL. Slope, intercept and coefficient of determination (r²) can be seen in the lower right corner. Pregnenolone (P5) and progesterone (P4) were significantly (P<0.05) and positively associated with dutasteride concentrations, while 5α-dihydroprogesterone (DHP) and allopregnanolone showed no association with dutasteride concentrations.

Figure 3

Figure 4
data on half-life of dutasteride in the horse are available, but in humans, the cited terminal half-life is approximately three to five weeks (Gisleskog et al. 1999, Evans & Goa 2003). For the current study, peak concentration of dutasteride in serum of treated mares was approximately 86 ng/mL (0.16 μM), well below the published IC$_{50}$ of dutasteride for equine 5α-reductase activity (1.0 μM) (Corbin et al. 2016). In contrast, the IC$_{50}$ for human type-1 isomorph of 5α-reductase was much lower (7 nM) suggesting that the equine isomorph of 5α-reductase is not as readily inhibited by dutasteride (Azzouni et al. 2012). The slow release of dutasteride from the myggil vehicle and the higher IC$_{50}$ for dutasteride against equine 5α-reductase may account for the observed lack of effect of dutasteride on DHP and other 5α-reduced pregnane concentrations in treated mares. However, P4 concentrations were increased sixfold above those of vehicle-treated mares. Because DHP concentrations at this stage of gestation are much higher than P4 concentrations in pregnant mares (approximately 50:1), small changes in DHP concentrations (of 5–6 ng/mL) due to inhibition of 5α-reductase would not be expected to be detectable against high background concentrations of DHP. The relatively low concentrations of P4 are likely to be a far more sensitive indicator for inhibition of 5α-reductase activity.

Based upon neonatal concentrations of dutasteride, this azasteroid crossed the equine placenta with neonatal concentrations approximately 50% of maternal concentrations in treated mares. Based upon neonatal concentrations of pregnanes, however, there did not appear to be an effect of dutasteride on fetal pregnane metabolism at these concentrations, as concentrations of P5, P4, DHP and allopregnanolone were not different in neonatal serum from treated and control groups.

Although 5α-reductase catalyzes the direct reduction of P4 to DHP, an alternative pathway for synthesis of DHP from P5 by which equine 5α-reductase directly metabolizes P5 to 3β-hydroxy-5α-pregn-20-one (3βP) with subsequent oxidation to DHP has been postulated (Schutzer & Holtan 1996, Schutzer et al. 1996). More recent reports indicate that pregnenolone is not a substrate for equine 5α-reductase derived from either the epididymis (Corbin et al. 2016) or from early equine trophoblast (Raeside et al. 2015) and that this alternative pathway for synthesis of DHP is likely not important in pregnane metabolism by the equine placenta.

Conclusions

Administration of the 5α-reductase inhibitor, dutasteride, to mares in late gestation increased maternal concentrations of P4 without detectable change in concentrations of DHP or other 5α-reduced pregnanes (20α5P, βα-diol or allopregnanolone). Dutasteride administration was also associated with increased placental weights postpartum and an apparent increase in retained fetal membranes. Although 5α-reductase activity is reduced in normal mares around parturition, the effects of inhibition of 5α-reductase on gestation length by administration of dutasteride to the mare remain unclear, and studies with larger animal numbers may be required to address potential effects of inhibition of 5α-reductase on parturition in the mare.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by the Albert G Clay endowment and by the Markey Trust of the University of Kentucky as well as by the John P Hughes Endowment of the University of California, Davis.

Acknowledgements

The authors wish to thank Jackie Barr and Brandon Wheying for their assistance in sample collection and animal care which made this project possible. The authors also wish to express gratitude to the staff at Maine Chance farm for equipment set up and collaboration during this study.

References


Aglhe O & Kolm HP 1975 Oestrogen and progesterone levels in the blood plasma of cows with normal parturition or with a retained placenta. Journal of Reproduction and Fertility 43 163–166. (https://doi.org/10.1530/jrf.0.0403163)


Belelli D & Lambert JJ 2005 Neurosteroids: endogenous regulators of the GABA(A) receptor, Nature Reviews Neuroscience 6 565–575. (https://doi.org/10.1038/nnr1703)


Canisso IF, Ball BA, Troedsson MH, Silva ES & Davolli GM 2013 Decreasing pH of mammary gland secretions is associated with parturition and is correlated with electrolyte concentrations in prefoaling mares. Veterinary Record 173 218. (https://doi.org/10.1136/vr.101658)


Chavatte P, Holtan D, Ousey JC & Rossdale PD 1997 Biosynthesis and possible biological roles of progestagens during equine pregnancy and


Ousey JC, Houghton E, Grainger L, Rossdale PD & Fowden AL 2005 Progesteragen profiles during the last trimester of gestation in Thoroughbred mares with normal or compromised pregnancies. Theriogenology 63 1844–1856.


